Neoangiogenesis Inhibitors (Sunitinib, Sorafenib, and Bevacizumab)
摘要
As a result of clinical studies, interstitial pneumonia is listed among important toxic events associated with the use of neoangiogenesis inhibitors. This information is included in the package insert. In this section, sunitinib, sorafenib, and bevacizumab, which were investigated in the post-marketing all-case survey are explained.